Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.

Earlier this year, J.P. Morgan released a report outlining the potential for GLP-1 treatments in other markets. Specifically, ...

Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

Eli Lilly (LLY) partners with British government for a first-of-its-kind real-world study on economic effects of its weight ...

The U.K. is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical ...

In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...

The justices are considering an effort challenging longstanding case law blocking the state’s ability to probe inflated drug ...

The company has committed £279 million ($364 million) to support national efforts aimed at reducing obesity, a critical ...